Do non harm can manifest in different ways. The previous cardioprotective supportive drugs have seemingly affected the efficacy of anti cancer drugs. I assume for an oncologist, this would be less desirable.
if a cardioprotective supportive drug also has the added benefit of being anti cancer, then I assume oncologists wouldn't hesitate to use this. I think anecdotally, this is shown on the triangle report where irrespective of whether there was strong or minimal additional anti cancer effect of the combo treatment, oncologist uptake was the same.
RAC media coverage, page-1840
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.030(2.01%) |
Mkt cap ! $254.2M | |||
| Open | High | Low | Value | Volume |
| $1.51 | $1.53 | $1.48 | $141.7K | 94.55K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 427 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 2999 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.51 |
Change
0.030 ( 0.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.52 | $1.53 | $1.48 | 13236 | ||
| Last updated 15.53pm 21/05/2024 ? | |||||
| RAC (ASX) Chart |